Toward commercialization of a novel fermentation product for enhancing intestine development and productivity of early-weaned pigs

用于增强早期断奶猪肠道发育和生产力的新型发酵产品的商业化

• 批准号: 470408-2014
• 负责人: Li, Julang
• 金额: $ 6.56万
• 依托单位: University of Guelph
• 依托单位国家: 加拿大
• 项目类别: Collaborative Research and Development Grants
• 财政年份: 2016
• 资助国家: 加拿大
• 起止时间: 2016-01-01 至 2017-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=598533
• 关键词: Toward; commercialization; novel; fermentation; product

Digestive upsets and growth reductions of newly-weaned pigs are key concerns in pig management. Establishing an intestinal development-enhancing diet will help to optimize pig performance at this critical stage. To this end, we have generated epidermal growth factor (EGF) - expressing L. lactis, and Pichia pastoris via a bioengineering approach. Previous trials in our laboratory have shown that EGF-producing L. lactis enhanced intestinal development and overall animal growth in both mice and pigs. Moreover, oral dosing of the fermentation product (after removal of the genetically modified microorganisms ) also increased intestinal development and growth of early-weaned pigs. To further this technology to commercial application, we plan to better characterize the GMO-free fermentation product, examine stability during feed processing, establish a dose-response relationship in newly-weaned piglets, and to validate the effectiveness of the fermentation product in an environment that represents commercial practices. In addition, we will perform evaluations in vitro and in vivo to determine the safety of application of the fermentation product. It is anticipated that the end product will offer a novel line of feed additives for commercial pork production, while reducing post-weaning growth lag and reliance on use of antibiotics and animal proteins in practical pig diets.

新断奶仔猪的消化障碍和生长减缓是养猪管理中的关键问题。建立肠道发育促进日粮将有助于优化猪在这一关键阶段的性能。为此，我们已经产生了表皮生长因子（EGF）表达L。乳酸菌和巴斯德毕赤酵母。本实验室先前的试验表明，产生EGF的L。乳酸促进小鼠和猪的肠道发育和整体动物生长。此外，口服发酵产品（去除转基因微生物后）也增加了早期断奶猪的肠道发育和生长。为了将这项技术进一步推向商业应用，我们计划更好地表征无转基因发酵产品，检查饲料加工过程中的稳定性，在新断奶仔猪中建立剂量-反应关系，并验证发酵产品在代表商业实践的环境中的有效性。此外，我们将进行体外和体内评价，以确定发酵产品应用的安全性。预计最终产品将为商业猪肉生产提供一系列新型饲料添加剂，同时减少断奶后生长滞后和对实际猪饲料中使用抗生素和动物蛋白的依赖。